Spectral AI Reports Q1 2026 Loss Amid FDA Review, BARDA Funding Boost

Event summary

  • Spectral AI reported a net loss of $3.4 million for Q1 2026, compared to a net income of $2.9 million in Q1 2025.
  • Research & Development revenue declined to $4.0 million from $6.7 million due to completed work under the base phase of the Project BioShield contract with BARDA.
  • The company received $31.7 million in advanced funding from BARDA for the accelerated second phase of its DeepView® System development.
  • Cash reserves decreased to $11.7 million from $15.4 million as of December 31, 2025.
  • Spectral AI reiterated its annual revenue guidance of approximately $18.5 million for 2026.

The big picture

Spectral AI's Q1 2026 results reflect the challenges of balancing development costs with regulatory milestones. The company's focus on medical diagnostics for wound care positions it within the broader trend of AI-driven healthcare solutions, but its success hinges on securing FDA approval and efficiently managing its cash reserves. The $31.7 million in BARDA funding provides a significant boost, but the path to commercialization remains uncertain.

What we're watching

Regulatory Approval
The timing and outcome of the FDA's determination on market authorization for the DeepView System will be critical for Spectral AI's commercialization plans.
Funding Utilization
How Spectral AI allocates the $31.7 million in BARDA funding will impact its ability to accelerate development and reduce future funding needs.
Cash Burn Rate
The pace at which Spectral AI depletes its cash reserves will determine its runway and potential need for additional financing.

Related topics

Revenue